Clinical trial
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de…
NCT00154297 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00154297 |
|---|---|
| Title | Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients |
| Official title | A National Multicentre Randomized Study Comparing the Early Versus Delayed Administration of Everolimus in de Novo Kidney Transplant Recipients at Risk of Delayed Graft Function |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus (RAD001) |
| Enrollment | 139 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 4, 2011 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: